LION bioscience AG Launches New Software For Genome Research: SRS everEST(TM)
SRS everEST(TM): Software for Clustering of Expressed Sequence Tags (ESTs)and Powerful Extension to LION's Suite of Solutions for Genome Research
HEIDELBERG, Germany, July 10 /PRNewswire/ -- LION bioscience AG (Nasdaq: LEON, Neuer Markt: LIO, WKN 504 350) today announced the release of SRS everEST(TM) 1.0, its new complete transcript reconstruction software, which LION expects to be of great use in the discovery and analysis of genes. The new module will complement LION's Life Science Informatics platform as the basis for its i-biology(R) solution, which is being developed to reengineer and shorten the life science industry's product development cycle. LION has already sold SRS everEST(TM) to customers including Nestle SA and Intervet Innovation GmbH.
"The majority of EST clustering tools do not go beyond the assembly stage. However, obtaining biological information about the EST consensus sequences and reconstructed genes is of utmost importance," said Dr. Paul Selzer, Head of Bioinformatics at Intervet Innovation GmbH. "With SRS everEST(TM) we can achieve this goal more quickly, because we can rely on the singular power of SRS in assigning functions to genes, as well as the robustness of state of-the-art clustering software. Within SRS everEST(TM), we now have a wealth of information from our own databases as well as from the public domain directly at hand."
SRS everEST(TM) enables efficient clustering of Expressed Sequence Tags (ESTs) as well as the assignment of biological information to the clusters. EST projects for more than 250 organisms are currently ongoing globally, with the number of projects expected to increase in the future. Through its direct link to LION's SRS data integration system, SRS everEST(TM) allows the unique assignment of biological information to gene sequences, while its advanced graphical representations enable intuitive and straight forward data analysis.
SRS everEST(TM) uses the latest EST clustering functionality provided by stackPACK(TM), which was developed by Electric Genetics (Capetown, South Africa). stackPACK(TM) is the only peer-reviewed clustering system available, and quickly constructs full- or extended-length gene sequences from fragmented data. Due to the specialized technology of stackPACK(TM), alternate expression or transcript variants can be identified, which may remain undetected with other EST clustering tools.
"SRS everEST(TM) is the first software on the market to facilitate quick assembly of ESTs and the connection of the resulting clusters with the wealth of biological data available in the public domain," said Dr. Jan Mous, Chief Scientific Officer at LION bioscience. "SRS everEST(TM) is an important new module in our suite of products for cutting-edge genomics research. It allows researchers to keep up with the increasing fast-paced developments in the field of genomics and transcriptomics."
For further information please refer to lionbioscience.com
About LION bioscience AG:
LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genetics to early and late discovery through clinical trials. LION offers these solutions via two primary lines of business:
* i-biology(R): the installation and implementation of enterprise-wide
horizontal information and knowledge management solutions as part of
LION's Life Science Informatics (LSI(TM)) line of business; and
* Integrated Drug Discovery and Diagnostics (iD3(TM)): application of
i-biology(R) to LION's internal drug discovery program with the goal
to out-license specific databases, polymorphism marker panels, and
validated targets and leads.
Founded in 1997, LION, together with its consolidated subsidiaries, has more than 465 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA and San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline Wellcome, GMD, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, Sumitomo Pharmaceuticals and Tripos.
All statements in this press release that are not historical are forward-looking statements within the meaning of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such as uncertainties relating to technologies, product development, or manufacturing, market acceptance, cost or pricing of LION's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent protection and litigation. These and other risk factors are discussed in LION's Registration Statement on Form F-4 declared effective by the SEC on February 9, 2001. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein.
LION bioscience(R) and i-biology(R) are either registered trademarks of LION bioscience AG in the United States and/or other countries, or LION bioscience AG has pending applications for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners. Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in the United States. Trega(R) is a registered trademark of Trega Biosciences, Inc.
For further information please contact:
LION bioscience
Dr. Andrea Kreisselmeier
Director Corporate Marketing & Communications
49-0-6221-4038-265
andrea.kreisselmeier@lionbioscience.com
Noonan/Russo Communications
Matthew Scampoli
1-212-696-4455 ext. 243
m.scampoli@noonanrusso.com
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE LION bioscience AG
CO: LION bioscience AG
ST: Germany, New York
IN: BIO MTC STW
SU: PDT
07/10/2001 01:30 EDT prnewswire.com |
